Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans

Drug Metabolism and Disposition

Volumn 31, Issue 3, 2003, Pages 319-325

  Imbert, Frédéric ^a   Jardin, Méryam ^a,c   Fernandez, Christine ^a   Charles Gantier, Jean ^b   Dromer, Françoise ^d   Baron, Gabriel ^e   Mentre, France ^e   Van Beijsterveldt, Ludy ^f   Singlas, Eric ^c   Gimenez, François ^a,c  

^a Département de Pharm Clin   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d INSTITUT PASTEUR   (France)

^e BICHAT HOSPITAL   (France)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ELACRIDAR; ITRACONAZOLE; PLACEBO;

ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BRAIN; CENTRAL NERVOUS SYSTEM INFECTION; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG METABOLISM; DRUG UPTAKE; MOUSE; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL;

ACRIDINES; ANIMALS; ANTIFUNGAL AGENTS; BRAIN; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; ISOQUINOLINES; ITRACONAZOLE; MICE; MICE, INBRED BALB C; P-GLYCOPROTEIN; PROTEIN TRANSPORT; TETRAHYDROISOQUINOLINES;

ANIMALIA; FILOBASIDIELLA NEOFORMANS; MURINAE;

EID: 0037372771     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.3.319     Document Type: Article

References (37)

1. Al-Abdely HM, Najvar L, Bocanegra R, Fothergill A, Loebenberg D, Rinaldi MG, and Graybill JR (2000) SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenzieie"). Antimicrob Agents Chemother 44:1159-1162.
2. Andreana A, Gollapudi S, and Gupta S (1994) Salmonella typhimurium induces expression of P glycoprotein (multidrug resistance 1 gene product) in a promonocytic cell line chronically infected with human immunodeficiency virus type 1. J Infect Dis 169:760-765.
3. Bailer AJ (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16:303-309.
4. Blasi E, Barluzzi R, Mazzolla R, Mosci P, and Bistoni F (1992) Experimental model of intracerebral infection with Cryptococcus neoformans: roles of phagocytes and opsonisation. Infect Immun 60:3682-3688.
5. Brown H, Hien TT, Day N, Mai NT, Chuong LV, Chau TT, Loc PP, Phu NH, Bethell D, Farrar J, et al. (1999) Evidence of blood-brain barrier dysfunction in human cerebral malaria. Neuropathol Appl Neurobiol 25:331-340.
6. 2.5] enkephaline by P-glycoprotein modulation. Pharm Res (NY) 16:296-301.
7. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, and Kim RB (2000) Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660.
8. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, and Melamed MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287.
9. Ding JC, Bauer M, Diamond DM, Leal MAE, Johnson D, Williams BK, Thomas AM, Najvar L, Graybill JR, and Larsen RA (1997) Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob Agents Chemother 41:1589-1593.
10. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, and Borst P (2000) Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer 83:366-374.
11. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, and Pastan I I (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265-269.
12. Gollapudi S, Reddy M, and Gangadharam P (1994) Mycobacterium tuberculosis induces expression of P-glycoprotein in promonocytic U1 cells chronically infected with HIV type 1. Biochem Biophys Res Commun 199:1181-1187.
13. Heykants J, Michiels M, Meuldermans W, Monbaliu J, Lavrijsen K, Van Peer A, Levron JC, Woestenborghs R, and Cauwenbergh G (1987) The pharmacokinetics of itraconazole in animals and man: an overview, in Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents (Fromtling RA ed) pp 223-249, Prous Science, S.A., Barcelona, Spain.
14. Huang ZH, Murakami T, Okochi A, Yumoyo R, Nagai J, and Takano M (2001) Expression and function of P-glycoprotein in rats with carbon tetrachloride-induced acute hepatic failure. J Pharm Pharmacol 53:873-881.
15. Huffnagle GB and McNeil LK (1999) Dissemination of C. noeformans to the central nervous system: role of chemokines, Th1 immunity and leukocyte recruitment. J Neurovirol 5:76-81.
16. Jalava KM, Partanen J, and Neuvonen PJ (1997) Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 19:609-613.
17. Jong AY, Stins MF, Huang SH, Chen SH, and Kim KS (2001) Traversal of Candida albicans across human blood-brain barrier in vitro. Infect Immun 69:4536-4544.
18. Kaukonen KM, Olkkola KT, and Neuvonen PJ (1997) Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther 62:510-517.
19. Lee G, Schlichter L, Bendayan M, and Bendayan R (2001) Functional expression of P-glycoprotein in rat brain microglia. J Pharmacol Exp Ther 299:204-212.
20. Litman T, Druley TE, Stein WD, and Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58:931-959.
21. Luabeya MK, Dallasta LM, Achim CL, Pauza CD, and Hamilton RL (2000) Blood-brain barrier disruption in simian immunodeficiency virus encephalitis. Neuropathol Appl Neurobiol 26:454-462.
22. Mager H and Göller G (1998) Resampling methods in sparse sampling situations in preclinical pharmacokinetic studies. J Pharm Sci 97:372-378.
23. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg ACLM, Schinkel AH, van de Vijver MJ, Scheper RJ, and Schellens JHM (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
24. Miyama T, Takanaga H, Matsuo H, Yamano K, Yamamoto K, Iga T, Naito M, Tsuruo T, Ishizuka H, Kawahara Y, and Sawada Y (1998) P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother 42:1738-1744.
25. Morris L, Silber E, Sonnenberg P, Eintracht S, Nyoka S, Lyons SF, Saffer D, Koornhof H, and Martin DJ (1998) High human immunodeficiency virus type I RNA load in the cerebrospinal fluid from patients with lymphocytic meningitis. J Infect Dis 177:473-476.
26. Ng WF, Sarangi F, Zastawny RK, Veinot-Drebot L, and Ling V (1989) Identification of members of the P-glycoprotein multigene family. Mol Cell Biol 9:1224-1232.
27. Patnaik A, Warner E, Michael M, Egorin MJ, Moore MJ, Siu LL, Fracasso PM, Rivkin S, Kerr I, Litchman M, and Oza AM (2000) Phase 1 dose-finding and pharmacockinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. J Clin Oncol 21:3677-3689.
28. Peck RA, Hewett J, Harding MW, Wang YM, Chaturvedi PR, Bhatnagar A, Ziessman H, Atkins F, and Hawkins MJ (2001) Phase 1 and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 19:3130-3141.
29. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, and Dismukes WE (2000) Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. J Infect Dis 30:710-718.
30. Saulsbury FT (2001) Successful treatment of Aspergillus brain abscess with itraconazole and interferon-γ in a patient with chronic granulomatous disease. Clin Infect Dis 32:137-139.
31. Savolainen J, Edwards JE, Morgan ME, McNamara PJ, and Anderson BD (2002) Effects of a p-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats. Drug Metab Dispos 30:479-482.
32. Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, and Okumura K (1999) Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull 22:1355-1359.
33. Tamai I, Yamashita J, Kido Y, Ohnari A, Sai Y, Shima Y, Naruhashi K, Koizumi S, and Tsuji A (2000) Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J Pharmacol Exp Ther 295:146-152.
34. Thiebaut F, Tsuoro T, Hamada H, Gottesman MM, Pastan I, and Willingham M (1989) Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and cross reactivity of one antibody with a muscle protein. J Histochem Cytochem 37:159-164.
35. Van Cutsem J (1993) Therapy of experimental meningeal and disseminated cryptococcosis. Mycoses 36:357-367.
36. Van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, Johnson PC, Tuazon CU, Kerkering T, Moskovitz BL, Powderly WG, and Dismukes WE (1997) Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 337:15-21.
37. Varga A, Sokolowska-Kohler W, Presber W, Von Baehr V, Von Baehr R, Lucius R, Volk D, Nacsa J, and Hever A (1999) Toxoplasma infection and cell free extract of the parasites are able to reverse multidrug resistance of mouse lymphoma and human gastric cancer cells in vitro. Anticancer Res 19:1317-1324.